Objective: Our objective was to assess survival, need for pacemaker insertion, and rejection frequency with a new surgical technique of orthotopic heart transplantation using bicaval and pulmonary venous anastomoses.
tal" orthotopic heart transplantation was described, the essential features of which are complete excision of the recipient atria and donor heart implantation with bicaval end-to-end anastomoses and pulmonary venous anastomoses. [4] [5] [6] This latter technique produces a nearly normal anatomic configuration of the atria and as a consequence offers the potential for more synchronous atrial contraction, elimination of the need for pacemaker implantation, and reduced atrioventricular valve regurgitation.
We report herein our clinical experience with 100 consecutive patients who underwent heart transplantation for which bicaval and pulmonary venous anastomoses were used.
Patients and methods
Patients. From December 1988 to October 1995, 171 patients underwent orthotopic heart transplantation at our institution. We retrospectively evaluated the 100 consecutive patients in whom the bicaval and pulmonary venous anastomotic technique was used between July 1991 and October 1995. We excluded seven patients in whom a modified technique, consisting of bicaval anastomoses for the right atrium and standard atrial anastomosis for the left atrium, 7 was used.
Surgical technique for donor heart harvesting. The donor's heart is harvested in the usual fashion with some technical modifications. The superior vena cava (SVC) is transected at or above the azygos vein. The inferior vena cava (IVC) is divided at the diaphragmatic reflection. The pulmonary veins are divided at their entrance into the pericardium, and then the cuffs of the superior and inferior pulmonary veins are joined by an incision to create a single left and single right orifice, leaving a bridge of intact posterior left atrial wall between them.
Surgical technique for recipient. Arterial cannulation is done in the standard fashion. For venous cannulation, the SVC is dissected free circumferentially, with the pericardial reflection being divided; the cannula is placed high on the vessel. The IVC is dissected free from the diaphragmatic reflection and cannulated low, as the IVC emerges from the diaphragm. The recipient heart is then explanted by transecting the SVC at the cavoatrial junction, and the IVC is divided with a generous cuff of right atrium. The left atrium is removed completely, leaving only two left atrial cuffs that include the ostia of the pulmonary veins on either side. The implantation of the donor's heart begins with the anastomosis of the left atrial cuff containing the left pulmonary veins to the corresponding orifice in the donor's left atrium. The right pulmonary veins are anastomosed in the same fashion. When both lungs are harvested, there may not be sufficient left atrial cuff for the cardiac allograft, in which case a modified technique can be used as described elsewhere. 7 The SVC and the IVC are then anastomosed in an end-to-end fashion. Frequently, however, the donor heart IVC has been transected close to or at the right atrium, to provide sufficient length for a liver allograft. In these circumstances, a generous cuff of right atrium around the recipient IVC will facilitate the end-to-end anastomosis. The aorta and pulmonary artery are reconstructed in the usual manner.
Immunosuppressive prophylaxis. All patients received an induction course of murine monoclonal antibody muromonab-CD3 (5 mg intravenously daily) (Orthoclone-OKT3; Ortho Biotech, Raritan, N.J.). The duration of this induction therapy changed from 14 to 10 days in November 1992 and has been 7 days since September 1993. All patients received an immunosuppressive regimen consisting of azathioprine 4 mg/kg intravenously before the operation and 2 mg/kg daily after the operation; methylprednisolone 500 mg intravenously at the time of crossclamp removal and 125 mg every 8 hours for three doses followed by oral prednisone 0.25 mg/kg daily during induction therapy, and thereafter 0.50 mg/kg. Oral cyclosporine 5 mg/kg twice daily was started within 48 to 72 hours after the operation, after renal function had stabilized. Prednisone was tapered over a period of 6 months to 1 year, according to the results of endomyocardial biopsies.
Postoperative follow-up. Endomyocardial biopsy, right heart catheterization, and thermodilution cardiac output were obtained at specified intervals after the operationP Mitral and tricuspid regurgitation were determined by means of Doppler echocardiography. Hemodynamic and echocardiographic data were excluded if patients had acute cellular rejection (grade ->IB according to the criteria of the International Society for Heart and Lung Transplantation 9) or humoral rejectionJ °' 11 Statistical analysis. Freedom from an event (death or rejection) was analyzed by means of life table methods and actuarial curves were compared by means of the log-rank test. A Cox stepwise regression was used in multivariate analyses. For each patient, cardiac output and cardiac index values closest to 2 weeks, 6 months, and 1 year after the operation were selected and were compared by means of an analysis of variance.
Data are summarized as mean -+ standard deviation for continuous variables and as frequencies and percents for categorical values. All testing was two-sided using an c~ level of 0.05, without adjustment for multiple testing.
Results

Preoperative recipient and donor characteristics.
The mean age of the patients was 57.0 _ 11.1 years and the range from 14 to 77 years. Fifty-one patients were more than 60 years old (mean age of 65.4 years for this group). The majority of the patients were male (92%) and white (82%), 11% were black, 3% Hispanic, and 4% Asian. The diagnoses were almost equally distributed between ischemic (52%) and idiopathic cardiomyopathy (44%). Four patients had other diagnoses: sarcoidosis (n = 1), doxorubicin (Adriamycin) toxicity (n = 1), congenital heart disease (n = 1), and amyloidosis (n = 1). The mean left ventricular ejection fraction was 19.5% and the average pulmonary artery systolic pressure was 51.7 + 19.2 mm Hg. No patient was declined because of pulmonary hypertension, but patients with elevated pulmonary vascular resistance were treated with vasodilators, including intravenous nitroglycerin, nitroprusside, or prostaglandin E 1 during the operative procedure and the perioperative period.
Donors were matched on the basis of blood type and body weight. The mean donor/recipient weight ratio was 0.92. A weight mismatch of more than 20% (donor/recipient weight ratio <0.8) occurred in 28 patients (28%).
Early (30-day) survival was 100% (Fig. 1) . One-and 2-year survivals were 98% _+ 2% and 96% _+ 2%, respectively. Recipient age and donor/recipient weight mismatch did not affect survival (p > 0.2 for each of these parameters). The same applies to the duration of OKT3 therapy. The survival curves of patients with the three durations of OKT3 therapy are shown in Fig. 2 . The seven late deaths were due to infections (n = 2), graft atherosclerosis (n = 3), acute rejection (n = 1), and nonspecific graft failure (n = 1). Postoperative cardiac output. Cardiac output and cardiac index were analyzed at 2 weeks, 6 months, and 1 year after transplantation. When patients with differing durations of OKT3 therapy were stratified and compared (data not shown), patients with a longer duration of OKT3 therapy demonstrated increased values for cardiac output and cardiac index at 2 weeks (p < 0.001), but not at later evaluations.
Postoperative Doppler echocardiography. One year after transplantation, 50 patients had Doppler echocardiographic evaluation. Of these, 11 (22%) had a degree of mitral regurgitation of 2+ or greater (10 had 2+ and one patient had 3+; scale 0 to 4+). Similarly, 18 (36%) had 2+ or more tricuspid regurgitation (16 patients had 2+ and two patients had 3+; scale 0 to 4+).
Treated rejection. Actuarial analysis of freedom
from treated rejection is shown in Fig. 3 , stratified according to the duration of OKT3 therapy. It is clear that treated rejection is less common i n p atients with only 7 days of therapy than in patients with 14 days of therapy (p < 0.0001). Similarly, the duration of OKT3 therapy was strongly related to the number of episodes of rejection in the first year after transplantation. Patients with 7 days of OKT3 therapy had a mean of 0.4 rejections in the first year, compared with 1.1 for patients with 14 days of OKT3 therapy (p = 0.0002).
Pacemaker placement. Insertion of a pacemaker
was not required in any patient within the first 6 months after transplantation, and all the patients were discharged in normal sinus rhythm. One patient required permanent pacemaker implantation 7 months after the operation for high-grade atrioventricular block.
Discussion
The concept of "total" orthotopic heart transplantation with bicaval and pulmonary venous anastomoses was first introduced by Dreyfus, 4 Yacoub, 12 and their associates. The surgical technique used in our center differs from that used by other groups in two important aspects: first, a portion of azygos vein is incorporated into the SVC anastomosis, which may reduce the occurrence of anastomotic stenosis (none since this modification has been used); second, two small buttons of atrial tissue are excised with the left and right pulmonary veins, instead of one large atrial button, thus allowing more donor left atrial tissue to be transplanted, possibly resulting in better left atrial function. We became interested in this technique because we noted a high incidence of permanent pacemaker requirement in the early postoperative period 13 (14% or nine of 64 patients) with the standard technique. Our initial intent to perform a randomized prospective trial comparing the traditional surgical technique with the new one was abandoned because of the uniform lack of need for permanent pacemaker insertion noted in the first 10 patients in whom the bicaval technique was used. For this reason, the decision was made to continue using the new technique so long as the patient was in normal sinus rhythm. This continues to be true for 124 consecutive patients, none of whom required a permanent pacemaker in the first 6 months after the operation and all of whom were discharged in normal sinus rhythm. This clear electrophysiologic advantage has been confirmed by other randomized and prospective trials. E1 Gamel and coworkers 14 randomized 40 patients to the bicaval technique and 35 patients to the standard technique. A permanent pacemaker was required in three patients with the standard technique versus none with the bicaval technique. They also noticed that the patients in whom the bicaval technique was used had significantly fewer tachyarrhythmias (2/40 versus 11/35 with standard technique). A similar incidence of atrial arrhythmias was found by Deleuze and colleagues 15 in a randomized study. Retrospective studies by Brandt, Harringer, and Hirt 16 and by Jeevanandam and coworkers 17 have demonstrated a decreased incidence of atrial flutter and fibrillation and sinus node dysfunction and improved survival in patients in whom the bicaval technique was used.
From an electrophysiologic standpoint, we can conclude that sinus node dysfunction and atrial bradyarrhythmias necessitating pacemaker insertion, which were recognized early in the transplant experience~S, 19 and attributed to the atrial incision, surgical trauma to the sinus node, and surgical distortion of the atrium after implantation, have been almost completely eliminated by the bicaval technique.
Atrioventricular valve function in the posttransplantation period has been studied by Doppler echocardiography in several reports. A surprisingly high incidence of mitral regurgitation (13/20 patients, 60%) and tricuspid insutficiency (17/20 patients, 85%) was observed by Angermann and associates z in patients in whom the standard technique was used. Stevenson and coworkers 3 confirmed these findings. The current study reveals that at 1 year, the incidence of tricuspid and mitral regurgitation was substantially lower in our patients when Fig . 3 . Actuarial freedom from treated rejection according to duration of OKT3 therapy. There was significantly greater freedom from treated rejection in patients treated with 7 days of OKT3, in comparison with 14-and 10-day courses. For the entire population, freedom from treated rejection was 64% _+ 5% at 30 days, 51% -+ 5% at 1 year, and 49% -+ 5% at 2 and 3 years. SE, Standard error.
compared with the literature reports. This improvement in atrioventricular valve function in patients in whom the bicaval technique was used has been documented by other authors, s who found less tricuspid regurgitation or less mitral regurgitation (or both) when these patients were compared with those in whom the standard technique was used. In one series by Leyh and associates, 2° this difference became apparent only during exercise. Atrial function after transplantation has also been the object of clinical and experimental investigation. In our institution, 21 left atrial transport and function were evaluated by means of Doppler echocardiography in transplant recipients and normal control subjects. We found that left atrial transport and ejection force were similar in normal control subjects and patients undergoing the new transplantation technique, but were significantly lower in the standard technique group. In another study using magnetic resonance imaging, 22 we found that the right and left atrial emptying fractions, as defined by the difference between atrial diastolic and systolic volumes divided by atrial diastolic volume, were significantly higher in the new technique group than in the standard technique group. Thus the bicaval and pulmonary venous anastomotic technique produces more physiologic atrial function than the biatrial technique, as evidenced by greater atrial ejection force and more normal atrial transport and atrial emptying fractions.
In an animal model, Goldstein and associates 23 have shown that synchronous atrial contractility constitutes an important compensatory response to right ventricular dysfunction. This finding was confirmed in patients with right ventricular infarction who manifested severely compromised cardiac function with right ventricular asynchrony or depressed A waves (an indication of right atrial dysfunction). Recent experimental work from Bittner, Chen, and Kendall 24 compares the two surgical techniques, with respect to atrial function, atrioventricular conduction, biventricular filling, and compliance in a dog model, using functional analysis, micromanometry, sonomicrometry, and ultrasonography. They conclude that atrial systole and right and left ventricular diastolic filling are better preserved with total orthotopic heart transplantation than with the standard technique.
The role of an intact right atrium in preventing the development of right ventricular failure after orthotopic heart transplantation, particularly in patients with marginally elevated pulmonary vascular resistance, is unknown. However, preliminary data from our institution 25 show lower mean right atrial and pulmonary arterial pressures and improved cardiac output after transplantation performed by During the course of the study, there was a change in our immunosuppression protocol. The duration of OKT3 therapy, in fact, was shortened from 14 to 7 days. To evaluate the impact of OKT3 duration on survival, the patients in whom the bicaval technique was used were grouped by duration of OKT3 therapy, and survival in the groups was compared by the log-rank test. Survival was not affected by the duration of OKT3 therapy, but the incidence of rejection was. As has been previously reported by us and by others, the patients with a 7-day course of induction therapy have an overall lower incidence of rejection because of a significantly lower incidence of humoral rejection, the incidence of cellular rejection being the same. Because the length of OKT3 therapy was also related to posttransplantation cardiac output, cardiac index, and mitral and tricuspid regurgitation, analysis of these latter outcomes was restricted to patients with 14 days of OKT3 induction therapy.
From our experience and from these studies, we can conclude that the bicaval and pulmonary venous anastomotic technique of total orthotopic heart transplantation, by preserving a more normal anatomic and geometric atrial configuration, has a clear electrophysiologic advantage, which is the elimination of the need for a permanent pacemaker. There is also a very low incidence of atrioventricular valve regurgitation. Clinical and experimental studies indicate that atrial function is improved with the bicaval technique and approaches that of a normal heart. The improved function conferred by the bicaval technique may be especially important in patients with high preoperative pulmonary vascular resistance and may lower the risk of postoperative right ventricular failure. 
Dr. Bartley P. Gritfith (Pittsburgh, Pa.). I would like to comment on the evolution of this surgical technique, then to comment on the results of Dr. Trento's series, and finally to ask Dr. Trento three questions. The technique of orthotopic cardiac transplantation began in the laboratories at Stanford and sprang into clinical acceptance through that group's work. Lower and Shumway have often been quoted for the technique, and it has withstood the test of time, with many patients benefiting. I suspect that the technique began to give way to a bicaval operation as opposed to a right atrial cuff technique when the domino procedure was introduced into cardiac transplantation. The potential benefits of the domino technique with bicaval anastomosis for the recipients were translated by the apparent reduction in atrial arrhythmia, and perhaps reduction in mitral regurgitation, as potentially a preferred method.
A number of groups subsequently studied bicaval anastomosis and incorporated the technique that Dr. Trento has just described--individual pulmonary vein anastomosis to the left atrium. Most notably, Mr. Yacoub and Dr. Dreyfus from Europe reported a series demonstrating this. Their results showed an increase in early cardiac output but most notably a small decrease in tricuspid regurgitation and a significant decrease in tricuspid regurgitation.
In the last few years Dr. Philippe DeLuz has also published a randomized study that includes an exercise component, bestowing the virtue of bicaval anastomosis and a small left atrial remnant. On the basis of that background, it would appear that Dr. Trento's group was well advised to enter into this trial.
I am struck by the stunning skill that Dr. Trento's group has demonstrated, not only with the technical aspects of this particular procedure, but also with the 100% inhospital survival. They demonstrate significant skill in their ability to select patients and care for them. I am going to disregard their references to the standard procedure, because these are noncontemporary control patients and probably represent a slightly different time era.
I have three questions for you, Dr. Trento. First, can you describe the proper performance of the SVC anastomosis? For instance, do you evert it? Have you seen any constrictions, and what do you about them? Have you had trouble fitting laterally displaced pulmonary veins removed from those patients who have a large left atrium back into the small donor heart that is to be placed? Second, is the early hemodynamic benefit that you propose the result of the preservation of sinus rhythm? If so, why is this benefit evanescent? Third, what is your explanation for the apparent reduction in mitral regurgitation with the total orthotopic transplant versus other less radical left atrial procedures? You have demonstrated that only 11 of 50 patients (22%) have mitral regurgitation, and this is the lowest number that I have seen published. Do you think this is solely because of the independent pulmonary venous anastomosis and more complete preservation of left atrial anatomy?
Dr. Trento. Thank you for your comments, Dr. Griffith. Early in our experience we did have one SVC stenosis. To avoid this complication, we transect the recipient SVC with 1 mm or 2 mm of right atrial cuff. We have used this technique in about 90 patients without any problem. We also used an azygos vein to enlarge the donor SVC stump. Regarding the surgical technique for the SVC anastomosis, we have tried the everting suture technique a few times, but we went back to the usual inverting, sewing from the inside technique, by using a very fine suture of 5 or 6-0 polypropylene and taking very small bites of tissue.
To answer your last question, regarding technical problems due to size discrepancy of the donor and the recipient's heart: If the IVC of the donor's heart is far away from the recipient's IVC stump, we align the right pulmonary veins, keeping in mind the IVC position. If we detect tension while we perform the IVC anastomosis, once the snaring tapes are released, the tension is completely released.
We do think that there is an early hemodynamic advantage with the new technique connected with the normal sinus rhythm in the patient. We have retrospectively examined our patients on the basis of their pulmonary vascular resistances, and we have seen that patients with high pulmonary vascular resistances have a lower right atrial pressure and pulmonary artery pressure with the bicaval technique than do the patients with the biatrial technique. Obviously these are retrospective reviews and their meaning is questionable.
Regarding the cause of mitral regurgitation, I think that by performing the individual pulmonary venous anastomosis you do obtain a normal-size left atrium. If you leave a posterior atrial cuff joining the two pulmonary veins, you will have a more enlarged left atrium with possibly abnormal atrial geometry. That is the only explanation that I can offer for the lower incidence of mitral regurgitation. were unable to achieve. After Sir Magdi Yacoub, we had proposed in 1991 this modified orthotopic transplant technique after a presentation by Angermann showing many morphologic and physiologic imperfections of the standard technique at transesophageal echocardiography. Since then we have performed more than 50 of those transplantations, but we were unable to prove any hemodynamic superiority at the early phase when comparing the two techniques. What we have seen is that we could avoid thrombus formation, which can occur with the standard technique and may lead to strokes.
Unlike you, we have had one pacemaker implantation after the modified technique but have a significant decrease in the incidence of arrhythmias. I therefore have three questions. How do you explain that you did not require pacemaker implantation with the modified technique? Would you agree that many of the atrioventricular blocks that are encountered after orthotopic transplantation may be related to the preservation technique more than to the surgical technique? Do you believe that hemodynamic superiority of the complete technique as opposed to the standard technique, which could not be demonstrated at rest, probably could be demonstrated with exercise. Are you intending to try to prove that? Finally, you have clearly shown a reduced incidence of both mitral and tricuspid regurgitation. We have found the same result. However, this fate is denied by those who favor the bicaval technique as opposed to the standard technique. Could you explain the difference between those two techniques with regard to mitral regurgitation?
Dr. Trento. To answer your last question, the bicaval and pulmonary vein anastomosis technique leaves a normal left atrial anatomy. I think the absence of a pacemaker requirement in our experience is due to the fact that we do not touch any of the conduction tissue in the atrium. Our preservation technique is the same that was used 15 years ago--the Stanford solution--so I do not think it is a question of preservation. Yes, we are in the process of doing exercise testing to determine whether the hemodynamic advantage of the new technique is more evident during exercise.
